Dyslipidaemia: what's around the corner?

This article reviews therapies in development to further lower LDL-cholesterol (Proprotein convertase subtilisin/kexin-9 (PCSK-9) inhibitors), raise HDL-holesterol (cholesterol ester transfer protein inhibitors (CETPIs)) and reduce triglycerides (novel peroxisome proliferator-activated receptor (PPAR)-agonists and omega-3 fatty acid preparations). Specialised therapies are in development for treatment of orphan disoders such as homozygous familial hypercholesterolaemia (lomitapide) or familial chylomicroaemia (alipogene tiparvovec). These novel lipid-lowering agents are likely to find uses in treating patients at the highest cardiovascular risk. PMID: 25468918 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/pubmed/25468918?dopt=Abstract

Source: Clinical Medicine - December 1, 2014 Category: Journals (General) Authors: Wierzbicki AS, Perera D, Ewang-Emukowhate M Tags: Clin Med Source Type: research